Skip to main content

Table 1 Effect of bosentan on blood pressure, exercise capacity and blood oxygen saturation

From: Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease

Parameter, mean ± SD (p value) Baseline Month 3 Month 6 Month 9b Month 12 Month 18 Month 24 Final follow-upa
SBP (mmHg) 125.7 ± 14.0 105.0 ± 11.8b (0.063) 111.7 ± 9.8b (0.125) 111.7 ± 5.2b (0.094) 114.3 ± 13.7 (0.250) 113.7 ± 9.6 (0.188) 106.4 ± 7.5 (0.063) 108.6 ± 9.0 (0.094)
DBP (mmHg) 80.0 ± 5.8 74.2 ± 8.6b (0.125) 79.2 ± 8.0b (1.000) 73.3 ± 11.7b (0.281) 69.3 ± 8.4 (0.031) 73.6 ± 8.5 (0.250) 68.9 ± 7.8 (0.063) 68.6 ± 4.8 (0.031)
6MWD (m) 199.6 ± 69.1 291.7 ± 73.1b (0.063) 260.7 ± 60.2b (0.063) 292.3 ± 112.7b (0.031) 301.6 ± 88.7 (0.016) 317.4 ± 105.8 (0.016) 291.9 ± 115.4 (0.016) 303.7 ± 99.9 (0.016)
SaO2 (%) at rest 81.7 ± 6.6 87.2 ± 5.6b (0.063) 88.4 ± 2.7 (0.031) 89.3 ± 2.5b (0.031) 89.0 ± 2.5 (0.016) 87.9 ± 4.5 (0.109) 89.3 ± 1.8 (0.031) 88.3 ± 3.2 (0.016)
SpO2 (%) before 6MWT 81.0 ± 6.6 87.0 ± 6.4b (0.094) 87.2 ± 3.8b (0.031) 89.3 ± 1.0b (0.031) 88.7 ± 3.1 (0.031) 88.6 ± 5.3 (0.047) 89.9 ± 1.8 (0.016) 88.0 ± 3.3 (0.016)
SpO2 (%) at end of 6MWT 61.6 ± 7.6 68.2 ± 9.3b (0.250) 67.7 ± 3.0b (0.063) 72.5 ± 6.2b (0.031) 70.6 ± 10.1 (0.078) 71.0 ± 7.5 (0.016) 74.3 ± 5.4 (0.016) 74.7 ± 6.2 (0.016)
Borg dyspnoea index 3.6 ± 1.4 2.3 ± 1.2b (0.063) 2.8 ± 1.5c (0.250) 3.2 ± 1.2b (1.000) 2.1 ± 1.2 (0.016) 2.9 ± 1.8 (0.313) 3.7 ± 2.9 (1.000) 2.4 ± 1.1 (0.250)
  1. SBP: systolic blood pressure; DBP: diastolic blood pressure; 6MWT: 6-minute walk test; SaO2: transcutaneous arterial oxygen saturation; SpO2: peak exercise transcutaneous arterial oxygen saturation.
  2. aWilcoxon signed-rank test (two-sided) on change from baseline statistically significant (p < 0.05).
  3. bn = 6 due to missing data.
  4. cn = 5 due to missing data.